Holen Sie sich die Stockscreener-App
8.655
1.92%
-0.185
Kura Oncology Inc Aktie (KURA) Neueste Nachrichten
Implied Volatility Soars for Kura Oncology Option Contracts - Bitget
Kura Oncology at Barclays Conference: Strategic Focus on Drug Combinations - Investing.com Canada
Implied Volatility Surging for Kura Oncology Stock Options - TradingView
(KURA) Risk Channels and Responsive Allocation - Stock Traders Daily
Kura Oncology Inc earnings missed by $0.66, revenue fell short of estimates - Investing.com Nigeria
Kura Oncology at Leerink Global Healthcare Conference: Strategic Expansion Insights - Investing.com Canada
KURA: Rapid market access and robust pipeline drive growth and leadership ambitions in precision oncology - TradingView
KURA: Multiple clinical readouts and strong commercial momentum position for leadership in targeted oncology - TradingView
FY2027 EPS Forecast for Kura Oncology Lowered by Analyst - MarketBeat
How The Kura Oncology (KURA) Story Is Shifting With Komzifti And New Street Targets - Yahoo Finance
Kura Oncology 2025 Financials: Q4 Loss Widens, Misses Analyst EstimatesNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Kura Oncology, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:KURA) 2026-03-06 - Seeking Alpha
Kura Oncology, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Kura Oncology Reports $0.92 Q4 Loss Even as KOMZIFTI Debuts With $2.1M in Sales - AlphaStreet
Kura Oncology (NASDAQ:KURA) Given New $36.00 Price Target at Wedbush - MarketBeat
Kura Oncology, Inc. (NASDAQ:KURA) Q4 2025 Earnings Call Transcript - Insider Monkey
Kura Oncology reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Kura Oncology (KURA) Grants Stock Options to New Employees - GuruFocus
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Kura Oncology Q4 Earnings Call Highlights - MarketBeat
Kura Oncology Inc (KURA) Q4 2025 Earnings Call Highlights: KOMZIFTI Launch Boosts Revenue Amid ... By GuruFocus - Investing.com Canada
Wedbush Cuts Kura Oncology Price Target to $36 From $38, Outperform Rating Maintained - marketscreener.com
Kura Oncology Inc (KURA) Q4 2025 Earnings Call Highlights: KOMZI - GuruFocus
Kura Oncology (KURA) Reports Strong Q4 2025 with KOMZIFTI Launch - GuruFocus
Kura Oncology, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Kura Oncology (NASDAQ:KURA) Shares Gap Down After Earnings Miss - MarketBeat
Kura Oncology (NASDAQ:KURA) Releases Quarterly Earnings Results, Misses Estimates By $0.20 EPS - MarketBeat
Earnings call transcript: Kura Oncology Q4 2025 sees significant earnings miss, stock dips - Investing.com
Kura Oncology (KURA) Reports Q4 Loss, Misses Revenue Estimates - sharewise.com
Kura Oncology Reports Q4 Earnings Miss - National Today
Kura Oncology 10-K: $67.5M revenue; R&D $251.1M, SG&A $120.0M - TradingView
Kura Oncology: Q4 Earnings Snapshot - KVUE
Kura Oncology: Fourth Quarter Financial Results Overview - Bitget
Kura Oncology (KURA) Faces Mixed Financial Results Amid Promisin - GuruFocus
Earnings Flash (KURA) Kura Oncology Posts Q4 Loss $0.92 a Share, vs. FactSet Est of $0.64 Loss - marketscreener.com
KURA ONCOLOGY ($KURA) Releases Q4 2025 Earnings - Quiver Quantitative
Kura Oncology Inc. Q4 Loss Increases - Nasdaq
Kura Oncology Reports Early Commercial Success for KOMZIFTI™ (ziftomenib) with Strong Initial Revenue and Payer Support - Quiver Quantitative
Kura Oncology Q4 Earnings Summary & Key Takeaways - Benzinga
Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Cancer pill KOMZIFTI begins sales as Kura posts $81M loss - Stock Titan
Kura Oncology at TD Cowen Conference: Strategic Growth and Innovation By Investing.com - Investing.com Canada
Kura Oncology (KURA) Set to Release Q4 Earnings - GuruFocus
A Glimpse of Kura Oncology's Earnings Potential - Benzinga
Kura Oncology Inc expected to post a loss of 61 cents a shareEarnings Preview - TradingView
Kura Oncology (KURA) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Wall Street Zen Downgrades Kura Oncology (NASDAQ:KURA) to Sell - MarketBeat
(KURA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Kura Oncology (NASDAQ:KURA) Upgraded at Zacks Research - MarketBeat
Kura Oncology, Inc. (NASDAQ:KURA) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
KURA Should I Buy - Intellectia AI
Kura Oncology, Inc. (KURA): Investor Outlook Reveals 275% Upside Potential - DirectorsTalk Interviews
KURA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Kura Oncology to Participate in Three Upcoming Investor Conferences - marketscreener.com
Biotech firm Kura Oncology maps three March investor talks - Stock Titan
Kura Oncology (NASDAQ:KURA) Rating Increased to Hold at Wall Street Zen - MarketBeat
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):